Hydroxy Compound Active Ingredients TRIZ Cases

Essential oil compounds replace synthetic histomonastats to treat histomoniasis while improving natural occurrence and animal acceptability.

A thermoplastic elastomer composition incorporates supersaturated CBD oil that migrates to the surface through bloom.

A polymeric matrix combines hyaluronic acid with a non-ionic polymer to modulate active ingredient release through hydration and gel formation.

Taxus cuspidata extract reduces eosinophil infiltration and IgE levels by blocking mast cell degranulation, addressing symptomatic relief limitations.

Ad.5/3-CTV replaces native adenoviral fibers with chimeric structures to bypass low CAR receptor levels and maintain therapeutic activity in malignant glioma.

Combines betel leaf extract, ginseng, and 4-allylpyrocatechol into a candy matrix.

Cannabidiol reduces acute and chronic graft-versus-host disease severity while minimizing adverse effects from conventional immunosuppressive drugs.

A three-dimensional amphipathic scaffold composition enhances microbiome resilience and hydration.

Natural compounds from plants and fungi treat viral respiratory infections by enhancing immune response while avoiding synthetic drug side effects.

Aluminum alkoxide mediates regioselective methylation of 2-tert-butyl hydroquinone, yielding >99.5% pure 2-BHA without complex recrystallization.

Oral hormone precursor delivery uses cannabinoid compounds to facilitate controlled absorption in canines.

Oral cannabinoid formulations with poloxamer enhance bioavailability to prevent cytokine release syndrome and ameliorate acute respiratory distress syndrome.

Optimizing pH to 3.90-4.10 stabilizes the pectin-agar composite network, preventing premature breakdown while ensuring rapid cannabinoid release.

Segmenting mucoadhesion into dispersed particles eliminates multi-layer complexity and patient discomfort during sustained buccal delivery.

An inert atmosphere in a sealed chamber drives decarboxylation at 70-150°C, preventing THC oxidation to cannabinol and preserving terpene content.

Uses specific concentrations of hydroxytyrosol, maslinic acid, and oleanolic acid to reduce mortality and improve weight gain without antibiotic resistance.

An alcoholic base adhesive forms a thin, translucent barrier that manages moisture and delivers antiviral agents without the thickness of hydrocolloid patches.

A bioerodible dosage delivery film incorporates cannabinoid-terpene-cyclodextrin complexes to enable direct buccal absorption.

Separate core-shell microcapsules with inorganic polymer shells preserve benzoyl peroxide and retinoid levels above 90% during storage.

Selenium-enriched yeast acts as an intermediary agent that mitigates radiotherapy side effects while enhancing treatment effectiveness.

Olive oil carries hydroxytyrosol and menthol in a gastro-resistant capsule, reducing inflammatory markers while avoiding gastric side effects.

A film-forming emulsion merges CBD, THC, and spearmint extract to enhance bioavailability.

Film-forming polymer encapsulates menthol and camphor in topical analgesic spray compositions.

A nutritional preparation combines organic mineral chelates, hemp oil, and niacinamide to enhance nutrient bioavailability.

Antibacterial nasal compositions containing thymol compounds and hydrogen peroxide modulate immunity to reduce viable pathogens.

A composition combining NHE1 inhibiting bioactive natural chemicals with anticancer drugs to suppress intracellular alkalinization.

Antioxidants buffer toxic side effects of DNMT1 inhibitors while preserving antiproliferative efficacy in cancer treatment.

Injectable sustained-release antioxidant formulations maintain therapeutic levels at ocular or tumor sites, resolving poor oral bioavailability.

Topical CBD and CBG compositions rebalance Th1/Th2 immune responses to inhibit melanocytic apoptosis, addressing autoimmune vitiligo side effects.

Aldehyde-based hoof treatments replace toxic copper and formaldehyde with safer alternatives that rapidly form a protective scab, reducing re-infection risks.

Formula I compounds bind viral nucleoprotein to prevent complex formation and reduce viral titer for treating RNA virus infections.

Magnolia bark extracts containing honokiol reduce cortisol concentrations by attenuating the Cortisol Awakening Response and suppressing systemic inflammation.

Ethyl maltol and surfactants stabilize aqueous CBD nanosuspensions below 100 nm, masking bitter flavor while improving bioavailability.

Targeting GPR55 receptors with fenoterol analogues overcomes resistance in cancers unresponsive to beta2-AR therapies.